DB19332InvestigationalProtein Based Therapies
Zifibancimig is under investigation in clinical trial NCT04567303, focusing on participants with neovascular age-related macular degeneration.
- Also known as
- Immunoglobulin G1 Fab fragment, bispecific, anti-(human vascular endothelial growth factor A and angiopoietin 2) (human monoclonal RO7250284 γ1-chain), disulfide with human monoclonal RO7250284 κ-chain · mmunoglobulin Fab G1-kappa, anti-[Homo sapiens ANGPT2 (angiopoietin 2, Ang2)] and anti-[Homo sapiens VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF), monoclonal antibody, bispecific, biparatope monovalent
- Code names
- RO-7250284
Resolves to
Compound
What you can answer from here — as of November 04, 2025
Which companies are running trials of Zifibancimig, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account